Scholars International Journal of Obstetrics and Gynecology (SIJOG)
Volume-2 | Issue-07 | 168-173
Original Research Article
A Study of Role of Prophylactic Magnesium Sulphate in Severe Preeclampsia in Preventing Eclampsia and Neonatal Outcome
P. Rajani, M. Radhika, R. Sarla Devi, T. Nirmala Kumari
Published : July 17, 2019
Abstract
The study included more of booked cases compared to unbooked. In booked cases most of them belonged to group to whom magnesium sulphate was not given (70% not given vs 59% given) and while in unbooked cases most of them were in group who received magnesium indicating poor control of blood pressure in unbooked cases. This confirms the high incidence of pre eclampsia in primigravida (69%given and 66% not given), more common in young women. The inclusion of more of preterm pregnancies represents the fact that termination of pregnancy is definitive treatment of pre eclampsia. Among the vaginal deliveries the instrumental delivery was significantly more in magnesium sulphate given group representing the tocolytic effect of magnesium sulphate. The complications of severe preeclampsia like eclampsia, pulmonary oedema and renal failure occurred more in group not given magnesium sulphate (2%,1%,1% given vs 11%, 3%, 4% not given) respectively and incidence of abruption and DIC in is almost similar in both groups (4% and 1% Vs 3%and 1%). Eclampsia is a grave complication of severe preeclampsia occurred more in the group not given magnesium sulphate compared to group given magnesium sulphate (11% vs 2%) indicating that intervention with magnesium sulphate has better maternal out come when given to women with severe pre eclampsia. The symptoms of toxicity like loss of deep tendon reflexes, oliguria and other side effects like nausea, head ache, flushing and vomiting had higher incidence in magnesium sulphate administered group. Nearly 40%-50% of new borns from both groups had good Apgar of 7-10 (40% given and 46% not given) respectively. Women with 3-6 Apgar were more in magnesium sulphate administered group (32% vs 10%) respectively in given and not given groups. Both groups had equal NICU admissions. When new born of more than 32 weeks, the salvageable neonates admitted to NICU were considered, the outcome was better in group given magnesium sulphate with no deaths pointing towards role of magnesium sulphate in improving fetal survival.